Analysts’ ratings for Mirum Pharmaceuticals (MIRM) over the last quarter have varied from bullish to bearish, as provided by four different analysts. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Rating | Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | Total Ratings |
|—————–|———|——————|————-|——————|———|—————|
| Last 30 Days | 0 | 1 | 0 | 0 | 0 | 1 |
| 1 Month Ago | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 Months Ago | 0 | 1 | 0 | 0 | 0 | 1 |
| 3 Months Ago | 2 | 0 | 0 | 0 | 0 | 2 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $55.25, a high estimate of $64.00, and a low estimate of $35.00. This current average represents a 19.93% decrease from the previous average price target of $69.00.
Analyzing Analyst Ratings: A Detailed Breakdown
A comprehensive examination of how financial experts perceive Mirum Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
– Josh Schimmer from Cantor Fitzgerald maintains an “Overweight” rating with a current price target of $35.00.
– Jonathan Wolleben from JMP Securities maintains a “Market Outperform” rating with a price target of $64.00.
– Steven Seedhouse from Raymond James lowers the rating to “Strong Buy” with a revised price target of $64.00 from $78.00.
– Ed Arce from HC Wainwright & Co. also lowers the rating to “Buy” with a price target of $58.00 from $60.00.
Key Insights:
– Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they ‘Maintain’, ‘Raise’ or ‘Lower’ their stance, it reflects their reaction to recent developments related to Mirum Pharmaceuticals.
– Rating: Delving into assessments, analysts assign qualitative values, from ‘Outperform’ to ‘Underperform’. These ratings communicate expectations for the relative performance of Mirum Pharmaceuticals compared to the broader market.
– Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Mirum Pharmaceuticals’s stock. This examination reveals shifts in analysts’ expectations over time.
Delving into Mirum Pharmaceuticals’ Background
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter “IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). The company is also involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. Additionally, they are developing volixibat for the treatment of adult patients with cholestatic liver diseases.
Breaking Down Mirum Pharmaceuticals’ Financial Performance
– Market Capitalization Analysis: The company’s market capitalization is above industry averages, reflecting substantial size and strong market recognition.
– Revenue Growth: Mirum Pharmaceuticals has achieved a noteworthy revenue growth rate of approximately 154.13% over the past 3 months, indicating a substantial increase in the company’s top-line earnings.
– Net Margin: The company’s net margin surpasses industry standards, highlighting exceptional financial performance.
– Return on Equity (ROE): Mirum Pharmaceuticals’ ROE is below industry standards, indicating difficulties in efficiently utilizing equity capital.
– Return on Assets (ROA): The company’s ROA exceeds industry averages, showcasing efficient use of assets and strong financial health.
– Debt Management: With a high debt-to-equity ratio, the company faces challenges in effectively managing its debt levels.
In conclusion, analysts’ ratings and price targets provide valuable insights into Mirum Pharmaceuticals’ market standing and performance. By understanding these evaluations alongside pertinent financial indicators, investors can make informed decisions. Stay informed and make strategic decisions with the Ratings Table provided.
